Anika Therapeutics | ANIK - Sales Revenues


Anika Therapeutics reported $30.62M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 12.59B 1.43B Jun/2026
Agenus USD 33.7M 500K Mar/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Halozyme Therapeutics USD 481M 104M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 425.49M 119.53M Jun/2026
Integra LifeSciences USD 418.8M 26.9M Jun/2026
Intrexon USD 717K 511K Jun/2024
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 83.7M 31.98M Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merit Medical Systems USD 418.8M 36.9M Jun/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.95B 710M Jun/2026
Smith & Nephew USD 1.6B 1.58B Jun/2026
Stryker USD 6.6B 600M Jun/2026
Veracyte USD 150.32M 11.25M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026
Zimmer Biomet Holdings USD 2.18B 90M Jun/2026